No Picture
News

Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Cell Therapy Scientific Advisory Board (SAB). The Cell Therapy SAB is comprised of industry and academic leaders in… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Mohab Hassanin, who joined the Company as Clinical Trial Manager. Click here to view original post… […]

No Picture
News

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results

SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2021 financial results after the U.S. financial markets close on Thursday, November 4, 2021. Oncternal’s management will host a… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

SAN DIEGO, Oct. 05, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR-NCI-EORTC Virtual International Conference… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies

SAN DIEGO and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, and Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics to Participate in September Investor Conferences

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the following conferences in the month of September: Click here to view original post… […]

No Picture
News

Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Affairs and Quality Assurance. Click here to view original post… […]

No Picture
News

Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the second quarter of 2021. Oncternal management will host a webcast today at 5:00 p.m. ET to provide a business… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. Click here to view original post… […]

No Picture
News

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the BTIG Virtual Biotechnology Conference being held August 9-10, 2021. Click here to view original post… […]

No Picture
News

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial markets close on Thursday, August 5, 2021. Oncternal’s management will host a… Click here to view original post… […]